Q2 EPS Estimate for Inovio Pharmaceuticals Cut by Analyst

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) – HC Wainwright reduced their Q2 2025 earnings per share estimates for Inovio Pharmaceuticals in a research note issued on Wednesday, May 14th. HC Wainwright analyst R. Selvaraju now expects that the biopharmaceutical company will post earnings per share of ($0.69) for the quarter, down from their prior forecast of ($0.55). HC Wainwright has a “Neutral” rating and a $3.00 price target on the stock. The consensus estimate for Inovio Pharmaceuticals’ current full-year earnings is ($4.23) per share. HC Wainwright also issued estimates for Inovio Pharmaceuticals’ Q3 2025 earnings at ($0.57) EPS, Q4 2025 earnings at ($0.49) EPS and FY2025 earnings at ($2.22) EPS.

Other equities analysts have also issued research reports about the company. Oppenheimer lowered their price objective on Inovio Pharmaceuticals from $15.00 to $13.00 and set an “outperform” rating for the company in a research report on Wednesday. StockNews.com lowered Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, May 12th. Finally, Royal Bank of Canada reissued a “sector perform” rating and set a $5.00 price objective on shares of Inovio Pharmaceuticals in a research report on Wednesday. One analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, Inovio Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $9.75.

Inovio Pharmaceuticals Trading Up 5.1%

Shares of Inovio Pharmaceuticals stock opened at $2.05 on Friday. The firm has a market capitalization of $75.18 million, a P/E ratio of -0.64 and a beta of 1.40. The business has a fifty day simple moving average of $1.80 and a two-hundred day simple moving average of $2.50. Inovio Pharmaceuticals has a 12 month low of $1.42 and a 12 month high of $12.62.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings data on Tuesday, May 13th. The biopharmaceutical company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($0.74) by $0.23. The firm had revenue of $0.07 million for the quarter, compared to analysts’ expectations of $0.01 million.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Nomura Holdings Inc. bought a new position in Inovio Pharmaceuticals during the first quarter valued at approximately $28,000. Alpine Global Management LLC bought a new stake in Inovio Pharmaceuticals in the 4th quarter worth approximately $31,000. Freedom Investment Management Inc. bought a new stake in shares of Inovio Pharmaceuticals during the 1st quarter valued at about $31,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Inovio Pharmaceuticals by 39.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 5,894 shares during the period. Finally, Bank of Montreal Can bought a new stake in shares of Inovio Pharmaceuticals during the 4th quarter valued at about $43,000. 26.79% of the stock is owned by institutional investors.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.